newsfilter
← Latest News
GlobeNewswire·

Scopus Biopharma Completes Recapitalization Designed To Enhance Shareholder Value

Warrants to Purchase Approximately 21 Million Scopus Shares Eliminated Scopus BioPharma's Pure Play Immuno-Oncology Subsidiary, Duet BioTherapeutics, Independently Valued at $25 Million Scopus Maintains Approximately